Earnings History Data for Zevra Therapeutics, Inc. (ZVRA) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Zevra Therapeutics, Inc.

KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
09-03-2026	AH		ZVRA	Zevra Therapeutics, Inc.	494.86	1.16	0.05	-0.67	Zevra Therapeutics, Inc. GAAP EPS of $0.19 beats by $0.14, revenue of $34.1M beats by $6.05M [3/9/2026 4:08 PM]	11.05	1.93 (21.11%)	10.99	1.87 (20.50%)	6.19 - 13.16	8,597,474	770,000	317,796
Zevra Therapeutics, Inc. GAAP EPS of $0.19 beats by $0.14, revenue of $34.1M beats by $6.05M [3/9/2026 4:08 PM] Zevra targets expanded patient reach with 52 annual MIPLYFFA enrollments while advancing European access [3/9/2026 7:38 PM] Zevra jumps 19% after Q4 EPS tops consensus estimates [3/10/2026 9:03 AM]
05-11-2025	AH		ZVRA	Zevra Therapeutics, Inc.	573.14	-0.01	-0.04	-0.69	Zevra Therapeutics, Inc. GAAP EPS of -$0.01 beats by $0.02, revenue of $26.1M misses by $0.54M [11/5/2025 4:28 PM]	9.13	-0.94 (-9.34%)	9.39	-0.68 (-6.75%)	6.19 - 13.16	2,672,764	1,460,000	74,258
Zevra Therapeutics, Inc. GAAP EPS of -$0.01 beats by $0.02, revenue of $26.1M misses by $0.54M [11/5/2025 4:28 PM] Zevra signals European expansion for MIPLYFFA as U.S. coverage reaches 66% following robust Q3 [11/5/2025 9:01 PM]
12-08-2025	AH		ZVRA	Zevra Therapeutics, Inc.	657.25	-0.06	1.43	-0.48	Zevra Therapeutics, Inc. Non-GAAP EPS of -$0.06 misses by $1.44, revenue of $25.88M beats by $3.39M [8/12/2025 4:10 PM]	9.45	-2.31 (-19.64%)	10.50	-1.26 (-10.71%)	6.19 - 13.16	6,543,258	990,000	55,100
Zevra Therapeutics, Inc. Non-GAAP EPS of -$0.06 misses by $1.44, revenue of $25.88M beats by $3.39M [8/12/2025 4:10 PM] Zevra signals continued MIPLYFFA momentum with 26% revenue growth and $150M PRV sale strengthening balance sheet [8/12/2025 8:44 PM] Zevra Therapeutics Inc (ZVRA) Q2 2025: Everything You Need To Know Ahead Of Earnings [Aug-11-25 09:27AM]
13-05-2025	PM		ZVRA	Zevra Therapeutics, Inc.	425.89	-0.06	-0.21	-0.40	Zevra Therapeutics GAAP EPS of -$0.06 beats by $0.13, revenue of $20.4M beats by $3.44M [5/14/2025 2:52 AM]	8.14	0.26 (3.37%)	8.41	0.54 (6.86%)	4.20 - 9.76	1,490,556	480,000	64,452
Zevra Therapeutics GAAP EPS of -$0.06 beats by $0.13, revenue of $20.4M beats by $3.44M [5/14/2025 2:52 AM] Zevra Therapeutics signals accelerated MIPLYFFA adoption and $148.3M capital infusion while expanding global reach [5/13/2025 10:46 PM]
11-03-2025	AH		ZVRA	Zevra Therapeutics, Inc.	432.35	-0.67	-0.39	-0.40	Zevra Therapeutics GAAP EPS of -$0.67 misses by $0.27, revenue of $12M beats by $3.07M [3/11/2025 4:54 PM]	7.89	-0.18 (-2.23%)	8.01	-0.06 (-0.74%)	4.20 - 9.76	1,049,491	440,000	188
Zevra Therapeutics GAAP EPS of -$0.67 misses by $0.27, revenue of $12M beats by $3.07M [3/11/2025 4:54 PM] Zevra Reports Full Year 2024 and Fourth Quarter Financial Results [2025-03-11 04:05PM] Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... [2025-03-12 03:06AM] Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates [Mar-11-25 06:15PM] Zevra Therapeutics: Q4 Earnings Snapshot [Mar-11-25 05:22PM] Q4 2024 Zevra Therapeutics Inc Earnings Call [2025-03-12 12:31PM]
12-11-2024	AH		ZVRA	Zevra Therapeutics, Inc.	473.56	-0.69	-0.44	-0.40	Zevra Therapeutics GAAP EPS of -$0.69 misses by $0.27, revenue of $3.69M misses by $1.17M [11/12/2024 4:26 PM]	8.65	0.08 (0.93%)	8.10	-0.47 (-5.48%)	3.89 - 9.09	1,055,709	620,000	20,323
Zevra Therapeutics GAAP EPS of -$0.69 misses by $0.27, revenue of $3.69M misses by $1.17M [11/12/2024 4:26 PM] Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates [2024-11-12 04:05PM] Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting [Nov-11-24 04:36PM] Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Know Ahead Of Earnings [Nov-11-24 07:15AM]
13-08-2024	AH		ZVRA	Zevra Therapeutics, Inc.	309.00	-0.48	-0.47	0.00	Zevra Therapeutics GAAP EPS of -$0.48 misses by $0.04, revenue of $445M beats by $440.64M [8/13/2024 5:01 PM]	6.97	0.19 (2.88%)	6.74	-0.04 (-0.59%)	3.89 - 8.44	1,012,174	2,300,000	3,762
Zevra Therapeutics reports Q2 results [8/14/2024 10:52 AM]
08-05-2024	PM		ZVRA	Zevra Therapeutics, Inc.	223.86	-0.40	-0.49	-0.34	Zevra Therapeutics GAAP EPS of -$0.40 beats by $0.08, revenue of $3.42M misses by $0.34M [5/8/2024 7:43 AM]	5.16	-0.01 (-0.29%)	5.16	0.0 (0.00%)	3.89 - 7.28	187,321	180,000	3,187
Zevra Therapeutics GAAP EPS of -$0.40 beats by $0.08, revenue of $3.42M misses by $0.34M [5/8/2024 7:43 AM] Zevra Therapeutics Q1 2024 Earnings Preview [5/7/2024 11:15 AM]
28-03-2024	AH		ZVRA	Zevra Therapeutics, Inc.	207.17	-0.40	-0.20	-0.26	Zevra Therapeutics GAAP EPS of -$1.30 misses by $0.12, revenue of $27.46M beats by $1.48M [3/28/2024 4:39 PM]	5.80	-0.14 (-2.36%)	5.43	-0.37 (-6.38%)	3.89 - 7.28	309,258	240,000	18,334
Zevra Therapeutics GAAP EPS of -$1.30 misses by $0.12, revenue of $27.46M beats by $1.48M [3/28/2024 4:39 PM]
07-11-2023	PM		ZVRA	Zevra Therapeutics, Inc.	157.11	-0.40	-0.29	-0.19	Zevra Therapeutics GAAP EPS of -$0.40 misses by $0.10, revenue of $2.89M misses by $0.49M [11/7/2023 7:38 AM]	4.41	-0.15 (-3.40%)	4.40	-0.16 (-3.51%)	4.05 - 6.44	154,898	110,000	3,532
Zevra Therapeutics Q3 2023 Earnings Preview [11/6/2023 11:26 AM] Zevra Therapeutics GAAP EPS of -$0.40 misses by $0.10, revenue of $2.89M misses by $0.49M [11/7/2023 7:38 AM]
14-08-2023	PM		ZVRA	Zevra Therapeutics, Inc.	169.07	-0.15	-0.39	-0.19	Zevra Therapeutics GAAP EPS of -$0.15 beats by $0.19, revenue of $8.5M beats by $5.47M [8/14/2023 7:47 AM]	5.38	0.18 (3.46%)	5.20	0.0 (0.00%)	4.05 - 6.92	149,110	120,000	6,771
Zevra Therapeutics GAAP EPS of -$0.15 beats by $0.19, revenue of $8.5M beats by $5.47M [8/14/2023 7:47 AM]
15-05-2023	AH	After the close (May 15)	ZVRA	Zevra Therapeutics, Inc.	147.14	-0.34	-0.26	-0.06	Zevra Therapeutics GAAP EPS of -$0.34 misses by $0.11, revenue of $2.88M beats by $0.19M [5/15/2023 4:14 PM]	4.68	0.32 (7.34%)	4.30	-0.06 (-1.38%)	4.03 - 6.92	317,892	250,000	707
Zevra Therapeutics GAAP EPS of -$0.34 misses by $0.11, revenue of $2.88M beats by $0.19M [5/15/2023 4:14 PM]
07-03-2023	PM	Before the open (Mar 7)	ZVRA	Zevra Therapeutics, Inc.	0.00	-0.26	-0.20	0.00	Zevra Therapeutics GAAP EPS of -$0.26 misses by $0.08, revenue of $2.3M misses by $0.8M [3/7/2023 7:49 AM]	4.25	-1.09 (-20.47%)	5.21	-0.14 (-2.62%)	4.00 - 6.92	1,255,977	150,000	17,592
Zevra Therapeutics GAAP EPS of -$0.26 misses by $0.08, revenue of $2.3M misses by $0.8M [3/7/2023 7:49 AM]